SAN DIEGO, August 8, 2025 — Beechinor, BiotechReporter.news — Oncolytics Biotech Inc. (Nasdaq: ONCY) (TSX: ONC) will voluntarily delist its common shares from the Toronto Stock Exchange (TSX) at the close of markets on August 22, 2025. The delisting will not affect the company’s Nasdaq listing. The board determined that delisting from the TSX is in the best interest of the company and its shareholders because the shares are already listed on the Nasdaq, and the company intends to maintain that listing. Also, Oncolytics will cease to be treated as a Foreign Private Issuer (for purposes of U.S. federal securities laws) effective January 1, 2026, and is considering re-domiciling to the U.S. in the future.
After delisting from the TSX, the shares will continue to trade on the Nasdaq under the symbol “ONCY.” Canadian shareholders will be able to continue to trade their shares on the Nasdaq through their brokers who have U.S.-registered broker-dealer affiliates. Oncolytics will continue to be a reporting issuer in the provinces and territories of Canada. Since the shares are listed on the Nasdaq (an acceptable alternative market), shareholder approval is not required under Section 720(b) of the TSX Company Manual.
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. It induces anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact.
Contact:
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Source: Oncolytics Biotech Inc.
